Krishna Pudi

Effect of Once-Daily Fluticasone Furoate/Vilanterol on 24-Hour Pulmonary Function in Patients With Chronic Obstructive Pulmonary Disease: A Randomized, Three-Way, Incomplete Block, Crossover Study

Joseph Boscia, Krishna Pudi, Michael T. Zvarich et al. · Clinical Therapeutics · 2012 · 48 citations

Asthma, Once-daily Fluticasone Furoate/vilanterol, Pulmonary Care +7

A 28-day, randomized, double-blind, placebo-controlled, parallel group study of nebulized revefenacin in patients with chronic obstructive pulmonary disease

Krishna Pudi, Chris N. Barnes, Edmund J. Moran et al. · Respiratory Research · 2017 · 31 citations · Full text

Improvements in Lung Function with Nebulized Revefenacin in the Treatment of Patients with Moderate to Very Severe COPD: Results from Two Replicate Phase III Clinical Trials

Gary T. Ferguson, Gregory Feldman, Krishna Pudi et al. · Chronic Obstructive Pulmonary Diseases Journal of the COPD Foundation · 2019 · 29 citations · Full text

Efficacy and safety of ipratropium bromide/albuterol delivered via Respimat® inhaler versus MDI

Richard ZuWallack, María Cristina De Salvo, Thomas Kaelin et al. · Respiratory Medicine · 2010 · 16 citations · Full text

Cardiovascular Disease, Pulmonary Medicine, Ipratropium Bromide/albuterol +2

24-h bronchodilation and inspiratory capacity improvements with glycopyrrolate/formoterol fumarate via co-suspension delivery technology in COPD

Colin Reisner, Gregory Gottschlich, Faisal Fakih et al. · Respiratory Research · 2017 · 16 citations · Full text